Abstracts tagged "Disease Activity"

Abstract Number: 350 • 2014 ACR/ARHP Annual Meeting
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Reena Khianey¹, Cristina Rozo², Sanjay Gupta³, Vivian P. Bykerk¹, Susan M. Goodman¹ and Alessandra B. Pernis⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²535 East 70th Street, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Rho-associated protein kinases (ROCKs) regulate cytoskeletal reorganization and gene expression through protein phosphorylation, and are implicated in the pathogenesis of a wide range of…
Abstract Number: 2890 • 2014 ACR/ARHP Annual Meeting
Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Since family history of RA is among the strongest risk factors for developing the disease, individuals suspected to have RA are routinely asked about…
Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 2126 • 2014 ACR/ARHP Annual Meeting
The Utility of Digital Activity Fluorescence Optical Imaging in Quantifying Hand and Wrist Inflammation in Rheumatic Diseases
Yogan Kisten¹, Noémi Györi¹, Hamed Rezaei^2,3, Adrian Levitsky⁴, Anna Karlsson¹, Erik af Klint³ and Ronald van Vollenhoven^3,5, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The rheumatology clinic of the Karolinska University Hospital, Stockholm, Sweden, ⁴The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ⁵Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose The objective detection and quantification of disease activity in its earliest pathophysiological stage is critical for achieving optimal therapy results. Fluorescence optical imaging (FOI)…
Abstract Number: 1577 • 2014 ACR/ARHP Annual Meeting
Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Philip J. Mease², Laura C. Coates³, Iain B. McInnes⁴, Maja Hojnik⁵, Alex Dorr⁶, Ying Zhang⁶, Benoit Guerette⁶, Alan Friedman⁶ and Dafna D. Gladman⁷, ¹University of California San Diego, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose The prediction of treatment outcomes based on early response could be useful in guiding decisions to adjust therapy. The objective was to determine if…
Abstract Number: 1147 • 2014 ACR/ARHP Annual Meeting
Economic Implications of Flares Among Patients with Early Rheumatoid Arthritis (RA)
James Signorovitch¹, Keith Betts¹, Vishvas Garg² and Yanjun Bao², ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Government mandated dose tapering and withdrawal of biologic treatments for RA after achievement of sustained disease control is currently observed in Taiwan, the Netherlands,…
Abstract Number: 701 • 2014 ACR/ARHP Annual Meeting
How Important Is Physical Activity for Patients with Systemic Lupus Erythematodes? -Results of Lula-Study
Isabelle Kloubert¹, Gamal Chehab¹, Jutta Richter², Rebecca Fischer-Betz³, Ralph Brinks² and Matthias Schneider¹, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ³Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany
Background/Purpose Physical activity (PA) plays a decisive role in primary and secondary prevention in various domains of medicine. Our examination aimed to determine association PA…
Abstract Number: 422 • 2014 ACR/ARHP Annual Meeting
Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA
Kubilay Sahin¹, Yasar Karaaslan^2,3, Zeynep Ozbalkan¹, Ahmet Omma¹ and Nesibe Yesil¹, ¹Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ²Rheumatology, Hitit University, Corum, Turkey, ³Ankara Numune Training and Research Hospital, Ankara, Turkey
Background/Purpose RAPID3 is an activity index based on only the patient's report in RA. It doesn’t require joint counts and it isn’t time consuming. Therefore…
Abstract Number: 348 • 2014 ACR/ARHP Annual Meeting
Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation?
Jeremy Sokolove¹, Harlan Sayles², Catriona Wagner³, Lauren J. Lahey¹, Geoffrey M. Thiele⁴, William H. Robinson¹, Andreas Reimold⁵, Gail S. Kerr⁶, Grant W. Cannon⁷ and Ted R. Mikuls², ¹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ⁴Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ⁶Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁷Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Cigarette smoking is a risk factor for RA and has been associated with increased disease severity and lower rates of disease remission. We examined…
Abstract Number: 2815 • 2014 ACR/ARHP Annual Meeting
Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy
T. Martijn Kuijper¹, J.J. Luime¹, P.H.P. de Jong², A. H. Gerards³, D. van Zeben⁴, I. Tchetverikov⁵, P.B.J. de Sonnaville⁶, M. van Krugten⁷, B. Grillet⁸, J.M.W. Hazes⁹ and A.E.a.M. Weel^10,11, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁷Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ⁸Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands, ⁹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹⁰Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ¹¹Rheumatology, MD, PhD, Rotterdam, Netherlands
Background/Purpose: To assess differences in frequency of biological therapy use and functional ability in early RA patients two years after starting induction therapy according to…
Abstract Number: 2498 • 2014 ACR/ARHP Annual Meeting
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose While synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) are often effective, treatment with such agents does not adequately control disease activity in all patients.…
Abstract Number: 2028 • 2014 ACR/ARHP Annual Meeting
Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort
Thomas Krams¹, Adeline Ruyssen-Witrand², Delphine Nigon¹, Bruno Fautrel^3,4,5, Francis Berenbaum^6,7, Alain G. Cantagrel⁸ and Arnaud Constantin⁹, ¹Rhumatologie, Purpan University Hospital, Toulouse, France, ²Rheumatology, Purpan University Hospital, Toulouse, France, ³Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁵Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁶Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, ⁷INSERM - UMR S 938, Paris, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁹Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with peak incidence in the fourth and fifth decades of age. To investigate whether age at disease…
Abstract Number: 1549 • 2014 ACR/ARHP Annual Meeting
The Swedish Early Psoriatic Arhtritis (SWEPSA) Registry 5-Yeear Follow-up: Slow Radiographic Progression with Highest Scores in Male Feet and in Patients with Baseline X-Ray Abnormalities
Elke Theander¹, Tomas Husmark², Ulla Lindqvist³, Per T Larsson⁴, Annika Teleman⁵, Gerd-Marie Alenius⁶ and Mats Geijer⁷, ¹Skane University Hospital Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Rheumatology, Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, ⁴Rheumatology, Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Rheumatology, Spenshult Rheumatological Hospital, Oskarström, Sweden, ⁶Rheumatology, Department of Public Health and Clinical Medicine, Rheumatology, Umeå University Hospital, Umeå, Sweden, ⁷Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden
Background/Purpose: The aim of this study is to describe early X-ray findings in psoriatic arthritis (PsA) patients from the SwePsA registry using the Wassenberg score,…
Abstract Number: 1062 • 2014 ACR/ARHP Annual Meeting
Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort
Christopher Sparks¹, Robert Moots¹, Eftychia Psarelli², Tom Huizinga³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Cancer Research UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Increased adiposity is associated with increased production of pro-inflammatory adipokines and raised inflammatory markers. As a result, standard disease activity scores (DAS) may be…
Abstract Number: 713 • 2014 ACR/ARHP Annual Meeting
Lupuspro Is Responsive to Changes in Disease Activity over Time
David Giangreco¹, Hervé Devilliers², Narender Annapureddy¹, Joel A. Block³ and Meenakshi Jolly¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patient reported outcome (PRO) tools are important to understand, educate, manage, and follow patients with systemic lupus erythematosus (SLE). Disease targeted PRO for SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].